ANDREW CIVITELLO to Risk Factors
This is a "connection" page, showing publications ANDREW CIVITELLO has written about Risk Factors.
Connection Strength
0.198
-
Does Gastrointestinal Bleeding Increase the Risk of Thromboembolic Events in Patients Supported With CF-LVADs? Artif Organs. 2026 Jun; 50(6):886-890.
Score: 0.021
-
Driveline Infections Among Patients Supported With Left Ventricular Assist Devices: A Single Center Sixteen-Year Longitudinal Profile. Artif Organs. 2026 Apr; 50(4):572-579.
Score: 0.021
-
Effect of Preoperative Mitral Regurgitation on LVAD Outcomes in Patients with Elevated Pulmonary Vascular Resistance. Cardiovasc Drugs Ther. 2025 10; 39(5):1085-1095.
Score: 0.019
-
Kidney Function Trajectories and Right Heart Failure Following LVAD Implantation. J Am Heart Assoc. 2024 03 05; 13(5):e031305.
Score: 0.019
-
The influence of preoperative dialysis on survival after continuous-flow left ventricular assist device implantation. Interact Cardiovasc Thorac Surg. 2022 02 21; 34(3):470-477.
Score: 0.016
-
Survival on the Heart Transplant Waiting List. JAMA Cardiol. 2020 11 01; 5(11):1227-1235.
Score: 0.015
-
Effect of cardiac arrest with aortic cross-clamping during left ventricular assist device implantation. Interact Cardiovasc Thorac Surg. 2020 01 01; 30(1):47-53.
Score: 0.014
-
Concomitant valve procedures in patients undergoing continuous-flow left ventricular assist device implantation: A single-center experience. J Thorac Cardiovasc Surg. 2019 10; 158(4):1083-1089.e1.
Score: 0.013
-
Incidence, Predictors, and Significance of?Ventricular Arrhythmias in Patients With?Continuous-Flow Left Ventricular Assist Devices: A 15-Year Institutional Experience. JACC Clin Electrophysiol. 2018 02; 4(2):257-264.
Score: 0.012
-
Outcomes of pre-emptive and rescue use of percutaneous left ventricular assist device in patients with structural heart disease undergoing catheter ablation of ventricular tachycardia. J Interv Card Electrophysiol. 2017 Jan; 48(1):27-34.
Score: 0.011
-
Continuous-flow ventricular assist device exchange is safe and effective in prolonging support time in patients with end-stage heart failure. J Thorac Cardiovasc Surg. 2015 Jan; 149(1):267-75, 278.e1.
Score: 0.010
-
Association between cell-derived microparticles and adverse events in patients with nonpulsatile left ventricular assist devices. J Heart Lung Transplant. 2014 May; 33(5):470-7.
Score: 0.009
-
A prospective feasibility trial investigating the use of the Impella 2.5 system in patients undergoing high-risk percutaneous coronary intervention (The PROTECT I Trial): initial U.S. experience. JACC Cardiovasc Interv. 2009 Feb; 2(2):91-6.
Score: 0.007
-
Use of the TandemHeart percutaneous ventricular assist device to support patients undergoing high-risk percutaneous coronary intervention. J Invasive Cardiol. 2006 Mar; 18(3):93-6.
Score: 0.005
-
Hemodynamic support with a percutaneous left ventricular assist device during stenting of an unprotected left main coronary artery. Tex Heart Inst J. 2004; 31(1):84-6.
Score: 0.005